Literature DB >> 15714749

The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants.

M Moriau1, E Lavenne-Pardonge, L Crasborn, R von Frenckell, C Col-Debeys.   

Abstract

Deep venous thromboses can be divided into two groups according to their pathogenesis, anatomical features and differing responses to therapy. The first and most frequent consists of so-called simple venous thrombosis while the second group, which is less common, comprises severe or recurrent venous thrombosis characterised by a multifactorial pathogenesis, a mixed thrombus rich in platelets and by an incomplete response to both prophylactic and therapeutic treatment with anticoagulants (heparin or vitamin K antagonist). In a randomized, prospective blind study in patients with severe or recurrent venous thrombosis, which included 6 groups each of 100 patients, co-administration of anticoagulants with various types of antiplatelet agent, either with rheological effects (piracetam, buflomedil, pentoxifylline) or without them (dipyridamole), has shown a beneficial potentiating antithrombotic effect with those drugs possessing rheological effects and the absence of this effect with dipyridamole.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 15714749     DOI: 10.1016/0049-3848(95)00081-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

Review 1.  Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism.

Authors:  D K Cundiff; J Manyemba; J C Pezzullo
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 2.  Antiplatelet agents for the treatment of deep venous thrombosis.

Authors:  Carolina Dq Flumignan; Luis Cu Nakano; Jose Cc Baptista-Silva; Ronald Lg Flumignan
Journal:  Cochrane Database Syst Rev       Date:  2022-07-25

Review 3.  Nutritional and anti-inflammatory interventions in chronic heart failure.

Authors:  Kamyar Kalantar-Zadeh; Stefan D Anker; Tamara B Horwich; Gregg C Fonarow
Journal:  Am J Cardiol       Date:  2008-06-02       Impact factor: 2.778

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.